Table 4

Tamoxifen-related biomarker changes in DL samples

Median Difference* by woman (n = 85)
ER LIKi-67 LICOX-2 LICytology
Median (IQ range)Median (IQ range)Median (IQ range)ImprovedWorsened
Tamoxifen−1.85 (−13.68-5.09)−0.16 (−0.65-0.00)−7.10 (−24.47-8.04)36% (14/39)13% (5/39)
n373636
Observation−0.62 (−6.52-4.09)0.00 (−0.12-0.21)−2.35 (−14.90-8.96)22% (10/46)17% (8/46)
n444141
Difference−1.23−0.16−4.75
P0.250.040.290.230.76
Median Difference* by matched duct (n = 146)
ER LIKi-67 LICOX-2 LICytology
Median (IQ range)Median (IQ range)Median (IQ range)ImprovedWorsened
Tamoxifen−7.06 (−16.42-6.63)−0.11 (−0.43-0.00)−2.97 (−24.27-8.01)23% (15/66)9% (6/66)
n585959
Observation−0.49 (−8.74-8.32)0.00 (−0.20-0.30)−3.02 (−13.33-8.94)18% (14/80)15% (12/80)
n717171
Difference−6.57−0.110.05
P0.050.0020.400.530.32
Adjusted P§0.070.030.400.450.27
  • *Six-month lavage minus baseline lavage.

  • Wilcoxon rank-sum test comparing medians between observation and tamoxifen groups.

  • Fisher's exact test comparing proportions between observation and tamoxifen groups.

  • §Wilcoxon rank-sum test comparing medians between observation and tamoxifen groups, adjusting for multiple ducts within women.

  • Donner and Klar test comparing proportions between observation and tamoxifen groups, adjusting for multiple ducts within women.